MedTrace Logo

Reveal In-Office Implants

NCT01168427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2018-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to gather evidence about the safety and feasibility of performing the implant procedure for the Reveal Insertable Cardiac Monitor (ICM) in an office or clinic setting rather than the traditional hospital operating room, cardiac catheterization or electrophysiology (EP) laboratory setting.

Conditions

  • Arrhythmias, Cardiac

Interventions

DEVICE

Reveal® DX or Reveal® XT Insertable Cardiac Monitor

Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.

Sponsors & Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

    lead INDUSTRY

Principal Investigators

  • Reveal In-Office Implants Clinical Research Specialist · Medtronic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168427 on ClinicalTrials.gov